Trials / Completed
CompletedNCT03307850
Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes
Feasibility Study to Assess the Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes on Sensor Augmented Insulin Pump
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sansum Diabetes Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will identify exercise-related and emotional stress related effects on glycemic control in patients with type 1 diabetes using sensor-augmented pump (SAP) therapy.
Detailed description
Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observation During Exercise and Stress | Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels. Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study. |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
- First posted
- 2017-10-12
- Last updated
- 2018-09-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03307850. Inclusion in this directory is not an endorsement.